Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ruijin Hospital | OTHER |
| Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | OTHER |
| West China Hospital | OTHER |
| Xiangya Hospital of Central South University |
Not provided
Not provided
Not provided
Not provided
Next-Generation Sequencing and whole transcriptome RNA sequencing were used to detect genomic variation and expression in tissues or blood, respectively. The treatment outcome of single targeted therapy or combined with immunotherapy was observed and followed up. Through this study, we intend to achieve RNA molecular classification of Chinese mRCC patients and to evaluate the correlation between ctDNA level, RNA molecular classification and treatment outcome, provide reference for metastatic RCC precise diagnosis and treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single targeted therapy | Active Comparator | sunitinib or pazopanib |
|
| targeted therapy combined with immunotherapy | Experimental | Programmed death-ligand 1 Inhibitor combined with axitinib |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| sunitinib or pazopanib | Drug | Single targeted therapy |
| |
| Measure | Description | Time Frame |
|---|---|---|
| progression-free survival | From drug taken until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months |
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate | From drug taken until the date of first documented progression, assessed up to 20 months |
Not provided
Inclusion Criteria:
Clinically diagnosed with renal cell carcinoma confirmed by pathology, including clear renal cell carcinoma and type I papillary renal cell carcinoma, type II papillary renal cell carcinoma, chromophobe renal cell carcinoma and renal cell carcinoma with sarcomatoid differentiation, etc
Exclusion Criteria:
• Previously received systematic treatment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| wei xue | Contact | 86-21-68383776 | xuewei@renji.com | |
| jiwei huang, M.D | Contact | 8613651682825 | huangjiwei@renji.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiao Tong University | Recruiting | Shanghai | Shanghai Municipality | 200127 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077210 | Sunitinib |
| C516667 | pazopanib |
| D000077784 | Axitinib |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
| OTHER |
| Fudan University | OTHER |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | OTHER |
| Second Affiliated Hospital of Nantong University | OTHER |
| Peking University First Hospital | OTHER |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | OTHER |
| Shanghai Jiao Tong University Affiliated Sixth People's Hospital | OTHER |
| Zhejiang University | OTHER |
| First Affiliated Hospital of Wenzhou Medical University | OTHER |
| Sir Run Run Shaw Hospital | OTHER |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | OTHER |
| The General Hospital of Eastern Theater Command | OTHER |
| The First Affiliated Hospital with Nanjing Medical University | OTHER |
| The First Affiliated Hospital of University of Science and Technology of China | OTHER |
| The Second Hospital of Anhui Medical University | OTHER |
| Tongji Hospital | OTHER |
| The First Affiliated Hospital of Zhengzhou University | OTHER |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | OTHER |
| Peking Union Medical College Hospital | OTHER |
| The First Affiliated Hospital of Shanxi Medical University | OTHER |
| Shanxi Province Cancer Hospital | OTHER |
| Changzhi Medical College | OTHER |
| First Affiliated Hospital Xi'an Jiaotong University | OTHER |
| Second Affiliated Hospital of Xi'an Jiaotong University | OTHER |
| The First Affiliated Hospital of Air Force Medicial University | OTHER |
| Tang-Du Hospital | OTHER |
| Quanzhou First Hospital | OTHER |
| Third Affiliated Hospital, Sun Yat-Sen University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| PD-1 inhibitor combined with axitinib |
| Drug |
targeted therapy combined with immunotherapy |
|
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D007211 |
| Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D001549 | Benzamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D001565 | Benzoates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D007191 | Indazoles |
| D011720 | Pyrazoles |